Copyright
©The Author(s) 2020.
World J Gastroenterol. Feb 28, 2020; 26(8): 777-788
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.777
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.777
| Screening within 30 d before donation start date |
| Exclusion criteria |
| Fever of unknown origin |
| Significant medical history other than resolved trauma or routine surgery |
| Abnormal body mass index (normal = 18.5 to 25.0) |
| Metabolic syndrome |
| Previous or current malignant condition |
| Atopic disease |
| Chronic pain syndrome |
| Irritable bowel syndrome |
| Idiopathic chronic constipation |
| Chronic diarrhea |
| Long term use of laxatives |
| Personal or family history of inflammatory bowel disease |
| History of Clostridioides difficile infection |
| Unexplained gastrointestinal illness |
| Autoimmune diseases |
| Neurological diseases |
| Active communicable illnesses (human immunodeficiency virus, chronic hepatitis etc.) |
| Travel to underdeveloped countries in past 12 mo |
| Hospitalization within the past 12 mo |
| Antibiotic exposure within the past 6 mo |
| High risk sexual behavior (men having sex with men, multiple sexual partners) |
| Health care worker |
| Illicit drug use, recent tattoos or incarceration |
| Immunosuppressive or antineoplastic medication use |
| Recent ingestion of certain common allergens (e.g. Nuts, shellfish, peanuts, eggs etc.) |
| Laboratory tests |
| High-sensitivity C-reactive protein assay |
| Lipid panel |
| Comprehensive metabolic panel |
| Complete blood count with differential |
| Antinuclear antibodies |
| Human chorionic gonadotrophin pregnancy test, if female |
| Infectious disease screening tests |
| Clostridioides difficile toxin gene polymerase chain reaction |
| Bacterial enteric pathogen stool culture |
| Rotavirus enzyme linked immunosorbent assay |
| Helicobacter pylori antigen |
| Vancomycin resistant enterococci rectal screen |
| Carbepenem resistant enterobacteriaceae plating |
| Nasal screen, plating |
| Listeria monocytogenes plating |
| Stool ova and parasites (including giardia, cryptosporidia and microsporidia) |
| Screening within 14 d before donation start date |
| Serology |
| Human immunodeficiency virus (HIV-1 and HIV-2) p-24 antigen and antibody |
| Syphilis enzyme immunoassay |
| Hepatitis A antibody |
| Hepatitis B surface antigen and surface antibody |
| Hepatitis C antibody |
| Plasma polymerase chain reaction assays for Epstein-Barr virus and Cytomegalovirus at first and last donations |
- Citation: Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: Past, present and future. World J Gastroenterol 2020; 26(8): 777-788
- URL: https://www.wjgnet.com/1007-9327/full/v26/i8/777.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i8.777